These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8230809)

  • 21. Development of a recombinant toxin fragment vaccine for Clostridium difficile infection.
    Karczewski J; Zorman J; Wang S; Miezeiewski M; Xie J; Soring K; Petrescu I; Rogers I; Thiriot DS; Cook JC; Chamberlin M; Xoconostle RF; Nahas DD; Joyce JG; Bodmer JL; Heinrichs JH; Secore S
    Vaccine; 2014 May; 32(24):2812-8. PubMed ID: 24662701
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clostridium difficile and Clostridium sordellii toxins, proinflammatory versus anti-inflammatory response.
    Popoff MR
    Toxicon; 2018 Jul; 149():54-64. PubMed ID: 29146177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated serum antibody response to toxin A following splenic abscess due to Clostridium difficile.
    Stieglbauer KT; Gruber SA; Johnson S
    Clin Infect Dis; 1995 Jan; 20(1):160-2. PubMed ID: 7727643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection.
    Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF
    Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Binary toxin-producing, large clostridial toxin-negative Clostridium difficile strains are enterotoxic but do not cause disease in hamsters.
    Geric B; Carman RJ; Rupnik M; Genheimer CW; Sambol SP; Lyerly DM; Gerding DN; Johnson S
    J Infect Dis; 2006 Apr; 193(8):1143-50. PubMed ID: 16544255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.
    Ghose C; Kalsy A; Sheikh A; Rollenhagen J; John M; Young J; Rollins SM; Qadri F; Calderwood SB; Kelly CP; Ryan ET
    Infect Immun; 2007 Jun; 75(6):2826-32. PubMed ID: 17371854
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunisation of mares with binding domains of toxins A and B of Clostridium difficile elicits serum and colostral antibodies that block toxin binding.
    Artiushin S; Timoney JF; Fettinger M; Fallon L; Rathgeber R
    Equine Vet J; 2013 Jul; 45(4):476-80. PubMed ID: 23206274
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biochemical and Immunological Characterization of Truncated Fragments of the Receptor-Binding Domains of C. difficile Toxin A.
    Huang JH; Shen ZQ; Lien SP; Hsiao KN; Leng CH; Chen CC; Siu LK; Chong PC
    PLoS One; 2015; 10(8):e0135045. PubMed ID: 26271033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simplified purification method for Clostridium difficile toxin A.
    Fu SW; Xue J; Zhang YL; Zhou DY
    World J Gastroenterol; 2004 Sep; 10(18):2756-8. PubMed ID: 15309736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.
    Kyne L; Warny M; Qamar A; Kelly CP
    N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.
    Wang YK; Yan YX; Kim HB; Ju X; Zhao S; Zhang K; Tzipori S; Sun X
    Hum Vaccin Immunother; 2015; 11(9):2215-22. PubMed ID: 26036797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of six murine monoclonal antibodies specific for toxin B of Clostridium difficile.
    Coughlin RT; Annunziato M; Roberson J; Marciani DJ
    Hybridoma; 1994 Apr; 13(2):147-52. PubMed ID: 8050780
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of toxemia in patients with Clostridium difficile infection.
    Yu H; Chen K; Wu J; Yang Z; Shi L; Barlow LL; Aronoff DM; Garey KW; Savidge TC; von Rosenvinge EC; Kelly CP; Feng H
    PLoS One; 2015; 10(4):e0124235. PubMed ID: 25885671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differentiation of Clostridium difficile toxin from Clostridium botulinum toxin by the mouse lethality test.
    Gilligan PH; Brown L; Berman RE
    Appl Environ Microbiol; 1983 Jan; 45(1):347-9. PubMed ID: 6824325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recombinant lipoprotein-based vaccine candidates against C. difficile infections.
    Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P
    J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.
    Kyne L; Warny M; Qamar A; Kelly CP
    Lancet; 2001 Jan; 357(9251):189-93. PubMed ID: 11213096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.
    Tian JH; Glenn G; Flyer D; Zhou B; Liu Y; Sullivan E; Wu H; Cummings JF; Elllingsworth L; Smith G
    Vaccine; 2017 Jul; 35(33):4079-4087. PubMed ID: 28669616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homogeneity and heterogeneity of toxins produced by Clostridium botulinum type C and D strains.
    Oguma K; Syuto B; Agui T; Iida H; Kubo S
    Infect Immun; 1981 Nov; 34(2):382-8. PubMed ID: 6171518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clostridium difficile lacks detectable superantigen activity.
    Wanahita A; Davis B; Hamill RJ; Goldsmith EA; Rodgers JR; Cook RG; Lamphear JG; Musher DM
    FEMS Immunol Med Microbiol; 2006 Jul; 47(2):275-7. PubMed ID: 16831215
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Production, purification and characterization of Clostridium difficile toxic proteins different from toxin A and from toxin B.
    Torres JF; Lönnroth I
    Biochim Biophys Acta; 1989 Oct; 998(2):151-7. PubMed ID: 2506935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.